Myocardial fibrosis: A cardiopathophysiological Janus face;Myokardfibrose: Ein kardiopathophysiologischer januskopf

Herz

Volumn 31, Issue 3, 2006, Pages 260-268

  Maisch, Bernhard ^a   Rupp, Heinz ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CATHEPSIN G; DIPEPTIDYL CARBOXYPEPTIDASE; ETANERCEPT; INFLIXIMAB; JANUS KINASE; TRANSFORMING GROWTH FACTOR BETA1; TRYPTASE;

CARDIOMYOPATHY; COLLAGEN SYNTHESIS; CONGESTIVE CARDIOMYOPATHY; ENDOCARDITIS; HEART FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; MYOCARDITIS; PHENOTYPE; REVIEW;

ANIMALS; ENDOMYOCARDIAL FIBROSIS; HEART; HUMANS; MODELS, CARDIOVASCULAR; MYOCARDIUM;

EID: 33745164918     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2823-9     Document Type: Review

References (28)

1. Alter P, Rupp H, Maisch B. Activated nuclear transcription factor κB in patients with myocarditis and dilated cardiomyopathy- relation to inflammation and cardiac function. Biochem Biophys Res Commun 2006;339:180-7.
2. Arakawa K, Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 2000;36:638-41.
3. Bastard JP, Jardel C, Delattre J, et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 1999;99:2221-2.
4. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-62.
5. Brilla CG, Rupp H, Maisch B. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz 2003;28:744-53.
6. Brilla CG, Scheer C, Rupp H. Angiotensin II and intracellular calcium of adult cardiac fibroblasts. J Mol Cell Cardiol 1998;30:1237-46.
7. Grotendorst GR, Duncan MR. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J 2005;19:729-38.
8. Iglarz M, Touyz RM, Viel EC, et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003;42:737-43.
9. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin 11 formation in human atherosclerotic aorta. Hypertension 1999;33:1399-405.
10. Janicki JS, Brower GL, Gardner JD, et al. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. Cardiovasc Res 2006;69:657-65.
11. Julius S, Krause L, Schork NJ, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens 1991;9:77-84.
12. Lamparter S, Schoppet M, Christ M, et al. Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion. Am J Cardiol 2005;95:1065-9.
13. Maisch B, Richter A, Sandmoller A, et al. Inflammatory dilated cardiomyopathy (DCMI). Herz 2005;30:535-44.
14. Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway.Brain Behav Immun 2005;19:493-9.
15. Reinehr T, Stoffel-Wagner B, Roth CL, et al. High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children. Metabolism 2005;54:1155-61.
16. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organisation/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93: 841-2.
17. Rupp H, Jaeger B. The renin-angiotensin system and the sympathetic nervous system in hypertension and congestive heart failure: implications for therapeutic interventions. J Clin Basic Cardiol 2001;4:47-51.
18. Rupp H, Maisch B. Radiotelemetric characterization of overweight-associated rises in blood pressure and heart rate. Am J Physiol 1999;277;H1540-5.
19. Rupp H, Rupp TP, Maisch B. Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure? Cardiovasc Res 2005;66:423-6.
20. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26.
21. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-70.
22. Theiss AL, Simmons JG, Jobin C, et al. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005;280:36099-109.
23. Tracey KJ. Fat meets the cholinergic antiinflammatory pathway. J Exp Med 2005;202:1017-21.
24. Vallon V, Wyatt AW, Klingel K, et al. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J Mol Med 2006:in press.
25. Vrijkotte TG, van Doornen LJ, de Geus EJ. Effects of work stress on ambulatory blood pressure, heart rate, and heart rate variability. Hypertension 2000;35:880-6.
26. Weber KT. Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. J Hypertens 2004;22:47-50.
27. Weber KT. The proinflammatory heart failure phenotype: a case of integrative physiology. Am J Med Sci 2005;330:219-26.
28. Weber KT, Sun Y, Guntaka RV. Rebuilding and remodeling following myocardial infarction: the good, the bad, and the ugly of tissue repair. Dialog Cardiovasc Med 1999;4:3-19.